Article
Merck touts new data for Keytruda combos in NSCLC at North American conference
Rating:
0.0
Views:
128
Likes:
1
Library:
1
Merck marched out new data from two studies on Friday to back king Keytruda — the drug that made the Big Pharma $11.1 billion last year — in advanced non-small cell lung cancer (NSCLC). At the IASLC 2020 North America Conference on Lung Cancer, Merck read out long-term data from
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value